Anaphylaxis Discharge Guidelines
All patients with anaphylaxis should be observed until symptoms fully resolve, with extended observation (up to 6 hours or longer) for those with severe anaphylaxis or requiring more than one dose of epinephrine, and every patient must be discharged with two epinephrine autoinjectors, written action plan, and allergy specialist referral. 1
Observation Period Duration
The observation time depends on risk stratification:
Low-Risk Patients (1 hour observation acceptable)
- Single epinephrine dose with complete symptom resolution
- No severe features at presentation
- Known trigger
- Good access to emergency care
- Adequate self-management skills
For these patients, discharge after 1 asymptomatic hour is reasonable 1, with recent quality improvement data supporting this shortened observation without increased biphasic reactions 2.
High-Risk Patients (Extended observation 6+ hours or admission)
Risk factors requiring longer monitoring include:
- Severe initial anaphylaxis (hypotension, hypoxia, persistent symptoms)
- Need for >1 dose of epinephrine (NNT to detect biphasic reaction = 13)
- Wide pulse pressure
- Unknown trigger
- Drug trigger in children
- Cardiovascular comorbidities
- Poor access to epinephrine or emergency services
- Poor self-management capability
The number needed to monitor with extended observation to detect one biphasic reaction is 41 for severe presentations and 13 for multiple epinephrine doses 1. While biphasic reactions occur in approximately 3-17% of cases, the case-fatality rate is 0.25-0.33% 1.
Mandatory Discharge Components
1. Epinephrine Autoinjector Prescription
2. Written Anaphylaxis Action Plan
- Personalized emergency instructions 7
- Recognition of anaphylaxis symptoms
- When and how to use epinephrine
- When to call emergency services
- Trigger avoidance strategies
3. Patient Education
Must cover:
- Biphasic reaction risk (can occur up to 72 hours later, though most within 6 hours) 1
- Specific symptom recognition (respiratory, cardiovascular, cutaneous, gastrointestinal)
- Trigger identification and avoidance
- Proper autoinjector technique
- Thresholds for seeking further care 1
4. Allergy Specialist Referral
- Mandatory for all patients 1, 3
- Purpose: trigger confirmation, comprehensive risk assessment, consideration of immunotherapy
- Timely follow-up essential for preventing recurrence
Medications at Discharge
What NOT to Prescribe for Biphasic Prevention
Do not routinely prescribe antihistamines or glucocorticoids to prevent biphasic reactions 1. These medications:
- Lack evidence for biphasic prevention
- May be used for symptom relief (antihistamines for urticaria/itching) during acute phase
- Should not delay or replace epinephrine
What IS Required
- Epinephrine autoinjectors (only proven intervention for biphasic reactions) 1
Common Pitfalls to Avoid
Discharging too early: All patients must be symptom-free before discharge, regardless of observation duration 1
Inadequate epinephrine prescribing: Only 14% of U.S. ED patients receive epinephrine at discharge 8—this is unacceptable standard of care
Missing high-risk features: Carefully assess for cardiovascular comorbidities, access barriers, and social support before shortened observation
Incomplete education: Verbal instructions alone are insufficient; written action plans significantly improve outcomes 9, 7
No specialist follow-up: Allergist referral is not optional—it's essential for trigger identification and immunotherapy consideration 1
Special Considerations
Patients with cardiovascular disease on beta-blockers or ACE inhibitors: Do not routinely discontinue these medications, as cardiovascular risk from stopping often exceeds anaphylaxis risk 4. Manage with shared decision-making.
Observation setting: Must be capable of managing recurrent anaphylaxis with immediate epinephrine access 1.